医药导报2019，Vol.38Issue(2)：187-192,6.DOI:10.3870/j.issn.1004-0781.2019.02.010
心脑血管疾病治疗药物共晶研究进展
Research Progresses on Pharmaceutical Co-crystals of the Cardiovascular and Cerebrovascular Diseases Treatment Drugs
摘要
Abstract
The pharmaceutical co-crystal has attracted a lot of attention in recent years as a new direction in the research of polymorphism drugs. The research on pharmaceutical co-crystal has scientific significance for improving the solubility, bioavailability and physical or chemical stability of drugs. In this paper, from the perspective of drugs for the treatment of cardiovascular diseases(including five major types: heart failure, hypertension, coronary heart disease and arrhythmia, stroke) , the latest research results of pharmaceutical co-crystal reported in recent years are reviewed, hope to provide reference for the follow-up research and promote the development of pharmaceutical co-crystal in China.关键词
治疗药物,心脑血管疾病/共晶/多晶型Key words
Treatment drugs,cardiovascular and cerebrovascular diseases/Co-crystal/Polymorphism分类
医药卫生引用本文复制引用
袁鹏辉,杨德智,胡堃,杜冠华,张丽,吕扬..心脑血管疾病治疗药物共晶研究进展[J].医药导报,2019,38(2):187-192,6.基金项目
国家重点研发计划(2016YFC1000900) （2016YFC1000900）
国家科技重大专项-重大新药创制(2017ZX09101001) （2017ZX09101001）
中国医学科学院医学与健康科技创新工程(2017-I2M-1-010) （2017-I2M-1-010）
药品医疗器械审评审批制度改革专项(ZG2017-4-02) （ZG2017-4-02）
